Active transcytosis and new opportunities for cancer nanomedicine

Pandit, Subrata; Dutta, Debapriya; Nie, Shuming

doi:10.1038/s41563-020-0672-1

Cited by 134 publications

(96 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 32 Little is currently known about the transcytosis process. 33 Recent studies have suggested that the positive charge of nanoparticles might promote transcytosis. 34 Therefore, the cationic liposomes used in this study might partially enhance their tumor-targeting effects, but the specific mechanism needs to be further studied in the future.…”

Section: Resultsmentioning

confidence: 99%

Liposomal Delivery of MicroRNA-7 Targeting EGFR to Inhibit the Growth, Invasion, and Migration of Ovarian Cancer

Cui

Song

et al. 2021

ACS Omega

View full text Add to dashboard Cite

Ovarian cancer is highly aggressive and has high rates of recurrence and metastasis. Due to the limited effects of current treatments, it is necessary to conduct research and develop new treatment options. The application of gene therapy in tumor therapy is gradually increasing and has exciting prospects. MicroRNA-7 (miR-7) has been reported to inhibit the growth, invasion, and metastasis of a variety of solid tumors. Cationic liposomes are safe and effective gene delivery systems for transfection in vivo and in vitro. To realize the application of miR-7 in the treatment of ovarian cancer, cationic liposomes were prepared with 1,2-dioleoyl-3-trimethylammonium-propane, 1,2-dioleoyl- sn -glycero-3-phosphoethanolamine, and cholesterol. The miR-7 liposomes had a suitable particle size, potential, and a high cellular uptake rate. MiR-7 encapsulated by liposomes could be effectively delivered to ovarian cancer cells and successfully targeted to the tumor site in a mouse xenograft model of ovarian cancer. In vitro and in vivo experiments revealed that the miR-7 liposomes had a significant ability to inhibit the growth, invasion, and migration of ovarian cancer, probably by inhibiting the expression of the epidermal growth factor receptor. Our studies of miR-7 liposomes demonstrated a safe and efficient microRNA delivery system for the gene therapy of ovarian cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Liposomal Delivery of MicroRNA-7 Targeting EGFR to Inhibit the Growth, Invasion, and Migration of Ovarian Cancer

Cui

Song

et al. 2021

ACS Omega

View full text Add to dashboard Cite

show abstract

“…In addition, novel studies such as the one by Sindhwani et al (2020) suggest that almost all injected nanoparticles enter solid tumors via active endothelial transcytosis instead of EPR [51]. Although these mechanisms of nanoparticle transcytosis and their ability to specifically target tumors still need clarification, they bear the potential to elicit a paradigm shift in the nanoparticle research field [52].…”

Section: The Tumor Microenvironment As a More Reliable Therapeutic Targetmentioning

confidence: 99%

Immune cells as tumor drug delivery vehicles

Combes

Meyer

Sanders

2020

Journal of Controlled Release

View full text Add to dashboard Cite

This review article describes the use of immune cells as potential candidates to deliver anti-cancer drugs deep within the tumor microenvironment. First, the rationale of using drug carriers to target tumors and potentially decrease drug-related side effects is discussed. We further explain some of the current limitations when using nanoparticles for this purpose. Next, a comprehensive step-by-step description of the migration cascade of immune cells is provided as well as arguments on why immune cells can be used to address some of the limitations associated with nanoparticle-mediated drug delivery. We then describe the benefits and drawbacks of using red blood cells, platelets, granulocytes, monocytes, macrophages, myeloid-derived suppressor cells, T cells and NK cells for tumor-targeted drug delivery. An additional section discusses the versatility of nanoparticles to load anti-cancer drugs into immune cells. Lastly, we propose increasing the circulatory half-life and development of conditional release strategies as the two main future pillars to improve the efficacy of immune cell-mediated drug delivery to tumors.

show abstract

“…Recently, the application of supramolecular gels in many elds has been receiving increasing attention, including sensors, cosmetics, oil-water separation, cell culture, drug delivery, and tissue engineering. [1][2][3][4] Low molecular weight gelators (LMWGs) self-assemble into supramolecular gels by non-covalent physical interactions (such as hydrogen bonding, p-p stacking, van der Waals forces, and dipole-dipole interactions) in specic solvents. [5][6][7] LMWGs can be classied into low molecular weight organogelators (LMOGs) and low molecular weight hydrogelators (LMWHs) based on the medium, in which (organic solvent or water) they form the gel.…”

Section: Introductionmentioning

confidence: 99%